APP and APLP2 Kunitz Domains Are Potent Endogenous Inhibitors of TMPRSS2 and Respiratory Virus Infection
Lawrenz, J.; Chatterjee, S.; Alfonso, A. R.; Stevaert, A.; Nchioua, R.; Templin, G.-M.; Fois, G.; Frick, M.; Naesens, L.; Gross, R.; Münch, J.
Show abstract
Respiratory viruses depend on host proteases for activation of viral fusion proteins, making these enzymes attractive targets for broad-spectrum antiviral strategies. We previously identified Trypstatin, a human Bikunin-derived Kunitz domain, as a potent endogenous inhibitor of the airway serine protease TMPRSS2. Here, we investigated whether TMPRSS2 inhibition is shared by additional human Kunitz domains. Kunitz domains with high sequence similarity to Trypstatin were synthesized, refolded, and functionally characterized. Domains derived from amyloid precursor protein (APP) and amyloid precursor-like protein 2 (APLP2) potently inhibited TMPRSS2, with APP displaying subnanomolar activity comparable to camostat mesylate. APP and APLP2 selectively blocked SARS-CoV-2 Spike-mediated entry without affecting VSV-G-mediated entry or cell viability and inhibited infection by multiple coronaviruses and influenza viruses, but not TMPRSS2-independent rhinovirus. In primary human airway epithelial cultures, APP and Trypstatin reduced replication of SARS-CoV-2, endemic coronaviruses, and influenza A virus, and remained stable in airway mucus. These findings identify APP and APLP2 Kunitz domains as potent endogenous inhibitors of TMPRSS2-dependent respiratory virus infection and promising scaffolds for host-directed broad-spectrum antivirals.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Susceptibilities of human ACE2 genetic variants in coronavirus infection 94%
- A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease 93%
- A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern 93%
Similar papers in this journal
- ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker 94%
- Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation 93%
- Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development 92%
Similar papers in this journal
- Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption 94%
- Nasal delivery of single-domain antibodies improve symptoms of SARS-CoV-2 infection in an animal model 93%
- Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models 93%
Similar papers in this journal
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 94%
- Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2 93%
- Defining the Substrate Envelope of SARS-CoV-2 Main Protease to Predict and Avoid Drug Resistance 93%
Similar papers in this journal
- Camel nanobodies broadly neutralize SARS-CoV-2 variants 94%
- An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. 93%
- Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.